Figure 2.
Effect of LY294002 and Akti-1/2 on cisplatin, paclitaxel, gemcitabine and topotecan-treated SKOV3 and IGROV1 cells. SKOV3 and IGROV1 cells were treated with LY294002 or Akti-1/2 alone (A), or cisplatin (B), paclitaxel (C), gemcitabine (D) or topotecan (E) in the absence or presence of inhibitor. Cell cycle distribution was quantified by flow cytometric analysis of propidium iodide-stained cells. Concentrations used: SKOV3: LY294002, 20 μM; Akti-1/2, 5 μM; cisplatin, 20 μg/ml; paclitaxel, 10 nM; gemcitabine, 100 nM; topotecan, 100 nM. IGROV1: LY294002, 10 μM; Akti-1/2, 5 μM; cisplatin, 5 μg/ml; paclitaxel, 10 nM; gemcitabine, 100 nM; topotecan, 250 nM. Results shown are representative of 3 or more independent experiments performed in duplicate.